Symbols

VCYT

Veracyte·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 5

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VCYT

Veracyte, Inc.

A genomic diagnostics company that develops and commercializes molecular diagnostic tests for cancer and other diseases

Industry

Healthcare Equipment and Supplies

Established Date

08/15/2006

Listing Date

10/30/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

824

Fiscal Year Ends

12-31

Website

www.veracyte.com

Security Type

Common stock

Office address

6000 Shoreline Court, Suite 300, South San Francisco, California 94080

Business

Introduction

Veracyte, Inc., was incorporated in Delaware on August 15, 2006 as Calderome Holding Company. Calderome operated as a startup park until early 2008. On March 4, 2008, the company changed its name to Veracyte Ltd. Veracyte is a pioneering diagnostic company in the field of molecular cytology to improve patient outcomes and reduce healthcare costs. The company specializes in achieving accurate diagnoses for diseases that often require invasive procedures — diseases where costly interventions by many healthy patients ultimately prove unnecessary. The company obtains clinically actionable genomic information from the collection of cytological specimens in outpatient clinics, improving the accuracy of diagnosis in patient care at an earlier stage. The company's first commercial solution, Afirma thyroid FNA analysis, includes gene expression classification (GEC) at its core. GEC helps physicians reduce the number of unnecessary surgeries by employing proprietary 142 genetic markers to preoperatively determine whether thyroid nodules previously classified as indeterminate by cytopathology can be reclassified as benign. The company's operations are headquartered in South San Francisco, California and Austin, Texas and it operates in a division.

Earnings Call

Q1/2025

Estimate EPS0.2

Actual EPS0.31

Estimate Revenue110.97M

Actual Revenue114.47M

Veracyte's Q1 2025: Unpacking Contradictions in Metastatic Revenue and Growth Expectations

May 08,2025 01:00·
Earnings Decrypt

Q2/2025

Estimate EPS0.3

Actual EPS0.44

Estimate Revenue120.90M

Actual Revenue130.16M

Veracyte's Q2 2025: Navigating the Contradictions in Decipher Growth, Prosigna Strategy, and Reimbursement Challenges

Aug 11,2025 09:21·
Earnings Decrypt

Company Financials

EPS

VCYT has released its 2025 Q3 earnings. EPS was reported at 0.51, versus the expected 0.32, beating expectations. The chart below visualizes how VCYT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VCYT has released its 2025 Q3 earnings report, with revenue of 131.87M, reflecting a YoY change of 13.82%, and net profit of 19.14M, showing a YoY change of 26.28%. The Sankey diagram below clearly presents VCYT's revenue sources and cost distribution.